Schneider Downs Wealth Management Advisors LP Acquires Shares of 2,980 Merck & Co., Inc. (NYSE:MRK)
Schneider Downs Wealth Management Advisors LP acquired a new stake in Merck & Co., Inc. (NYSE:MRK) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,980 shares of the company’s stock, valued at approximately $247,000.
Several other institutional investors and hedge funds have also made changes to their positions in MRK. Toth Financial Advisory Corp acquired a new stake in shares of Merck & Co., Inc. during the second quarter worth about $32,000. Lake Point Wealth Management raised its stake in Merck & Co., Inc. by 159.0% during the 1st quarter. Lake Point Wealth Management now owns 518 shares of the company’s stock valued at $40,000 after acquiring an additional 318 shares during the last quarter. Provident Wealth Management LLC purchased a new stake in Merck & Co., Inc. during the 3rd quarter valued at approximately $43,000. Estate Counselors LLC acquired a new stake in Merck & Co., Inc. during the 2nd quarter worth approximately $45,000. Finally, Watson Rebecca purchased a new position in shares of Merck & Co., Inc. in the 2nd quarter valued at approximately $48,000. Institutional investors and hedge funds own 73.18% of the company’s stock.
Several equities analysts have issued reports on the company. SVB Leerink boosted their target price on Merck & Co., Inc. from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 25th. JPMorgan Chase & Co. lifted their target price on shares of Merck & Co., Inc. from $98.00 to $105.00 and gave the stock an “overweight” rating in a research report on Friday. Mizuho reissued a “buy” rating on shares of Merck & Co., Inc. in a report on Tuesday, September 22nd. ValuEngine lowered shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Thursday, October 1st. Finally, Morgan Stanley reiterated a “buy” rating and set a $89.00 target price on shares of Merck & Co., Inc. in a research report on Tuesday, June 23rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $95.08.
Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Friday, July 31st. The company reported $1.37 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.14 by $0.23. Merck & Co., Inc. had a net margin of 22.20% and a return on equity of 52.94%. The firm had revenue of $10.87 billion for the quarter, compared to the consensus estimate of $10.52 billion. During the same quarter in the previous year, the firm posted $1.30 EPS. The firm’s quarterly revenue was down 7.6% on a year-over-year basis. On average, analysts forecast that Merck & Co., Inc. will post 5.68 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th were given a dividend of $0.61 per share. This represents a $2.44 dividend on an annualized basis and a dividend yield of 3.06%. The ex-dividend date was Monday, September 14th. Merck & Co., Inc.’s payout ratio is 47.01%.
In other news, CFO Robert M. Davis sold 251,273 shares of the firm’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $81.03, for a total transaction of $20,360,651.19. Following the completion of the sale, the chief financial officer now owns 422,329 shares of the company’s stock, valued at $34,221,318.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Frank Clyburn sold 18,876 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $81.55, for a total transaction of $1,539,337.80. Following the completion of the sale, the executive vice president now owns 99,639 shares of the company’s stock, valued at approximately $8,125,560.45. The disclosure for this sale can be found here. In the last quarter, insiders sold 280,529 shares of company stock worth $22,761,633. Insiders own 0.28% of the company’s stock.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Further Reading: What is a CD ladder?
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.